KI-Beratung Beta

Produktbild: Nanobiomaterials and Nanomedicines for Metabolic Disorders
- 13%

Nanobiomaterials and Nanomedicines for Metabolic Disorders

13% sparen

203,99 € UVP 235,50 €

inkl. gesetzl. MwSt., Versandkostenfrei


Beschreibung

Nanobiomaterials and Nanomedicines for Metabolic Disorders delves into the transformative role of nanotechnology in addressing metabolic disorders. The book begins with an overview of nanoparticle classifications and then explores the synthesis of biomaterials and drug delivery systems. In addition,...

Beschreibung

Nanobiomaterials and Nanomedicines for Metabolic Disorders delves into the transformative role of nanotechnology in addressing metabolic disorders. The book begins with an overview of nanoparticle classifications and then explores the synthesis of biomaterials and drug delivery systems. In addition, it explores innovative diagnostic and imaging techniques while presenting cutting-edge therapeutic approaches. Later chapters focus on specific metabolic disorders, such as cardiovascular and lifestyle-related conditions. The book is tailored to researchers, students, and healthcare professionals seeking advanced theranostic approaches to these disorders. By bridging nanotechnology with metabolic pathways, the text offers insights into how targeted nanomedicines can improve therapeutic outcomes.

Portrait

Dr. Subhash C. Mandal, PhD is Professor at Division of Pharmacognosy, Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India. Professor Mandal is the recipient of prestigious awards including Endeavour Research Award, Government of Australia; Distinguished Education & Research Award, AAiPS, USA; Talented Scientist Award, University of Colombo, Sri Lanka; SAARC Fellowship Award, University Grants Commission (UGC), Bangladesh; Fast Track Young Scientist Award, Department of Science and Technology , UGC Research Award, India and Outstanding University Teachers' Award , Department of higher education , Government of West Bengal , India. He has supervised more than 30 doctoral and 25 M. Pharm scholars and has more than 300 research publications, several patents, books and book chapters to his credit. Professor Mandal has delivered more than 50 research presentations around the globe, has chaired many international conferences, and successfully completed more than 10 government-funded research projects. He is reviewer and board member of several high-impact journals and is a recognized host scientist for many international research programs with developing countries sponsored by the Indian Government. He has visited more than 30 countries for various scientific deliberations, collaborations and exchange programmes.Dr. Nilanjan Ghosh is working as an Assistant Professor in the Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India. He has completed his M Pharm from BHU (2008) and PhD from Jadavpur University (2017), India. He is serving as an academician for last 13 years. His research interest involves drug discovery for metabolic and inflammation related disorders. He has supervised more than 10 M.Pharm scholars and has more than 15 research publications, and 6 book chapters to his credit. He is reviewer and board member of several high-impact journals.

Dr. Amit Kumar Halder is an Associate Professor at the Dr. B.C. Roy College of Pharmacy and Allied Health Sciences, West Bengal, India. He is also Joint Division-in-Charge in the Division of Pharmaceutical Chemistry at the same institute. He received his Ph.D. in Pharmacy from Jadavpur University, India, in 2016. He has five years of teaching experience and five years of postdoctoral experience. He worked as a postdoctoral researcher in University of Kwazulu-Natal, South Africa for one year and in University of Porto, Portugal, for four years. His specialization is computational chemistry, synthetic medicinal chemistry and cancer biology. He has published 58 articles in international journals and four book chapters.

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

08.12.2025

Herausgeber Subhash C. Mandal + weitere
Verlag Elsevier Science & Technology

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

08.12.2025

Herausgeber
Verlag Elsevier Science & Technology
Seitenzahl

582

Maße (L/B/H)

23/15,2/2,8 cm

Gewicht

975 g

Sprache

Englisch

ISBN

978-0-443-28942-2

EU-Ansprechpartner

Elsevier B.V.
Radarweg 29
1043 NX Amsterdam
NL
productsafety@elsevier.com

Herstelleradresse

Elsevier Science & Technology
London Wall 125
EC2Y 5AS London
GB
tradeorders@elsevier.com

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)

  • Produktbild: Nanobiomaterials and Nanomedicines for Metabolic Disorders
  • Section I: Nanomedicines for metabolic disorders: drug delivery
    1. Clinical use of inorganic and organic nanoparticles in metabolic syndromes
    2. Application of nanomedicines in mitigating oxidative stress
    3. Nanomedicines to enhance oral bioavailability for metabolic disorders
    4. Nanotechnology for the therapeutic use of biologics to treat metabolic disorders

    Section II: Nanotechnology in metabolic disorders: diagnosis and therapy
    5. Application of quantum dots in metabolic disorders
    6. Medical imaging using nanotechnology
    7. Nanorobotics: applications in metabolic disorders
    8. Nanomaterials for three-dimensional printing in management of metabolic disorders

    Section III: Nanomedicines for lifestyle metabolic disorders
    9. Nanomedicines to alleviate hepatic metabolic disorders
    10. Role of nanomedicines in type 2 diabetes
    11. Nanomedicines for precise therapy in hyperlipidaemia & obesity

    Section IV: Nanomedicines for cellular metabolic disorders
    12. Application of nanotechnology in lysosomal storage diseases
    13. Nanotechnology to target autophagy-mediated metabolic disorders
    14. Application of nanomedicines in glycogen storage diseases

    Section V: Nanomedicines for metabolic cardiovascular diseases
    15. Nanotechnology for metabolic vascular diseases
    16. Nanomedicines for the management of atherosclerosis